RZLT Stock Price, Rezolute, Inc. Quote, Chart

Market Summary

USD2.85-0.69

Market Closed

-19.49%

RZLT Alerts

3 major insider buys recently.

RZLT Stock Price

View Fullscreen

RZLT RSI Chart

RZLT Valuation

Market Cap

140.3M

Price/Earnings (Trailing)

-2.47

Price/Sales (Trailing)

24.76

Price/Free Cashflow

-2.65

RZLT Price/Sales (Trailing)

RZLT Profitability

Return on Equity

-61.97%

Return on Assets

-55.65%

Free Cashflow Yield

-37.8%

RZLT Fundamentals

RZLT Revenue

Revenue (TTM)

5.7M

Rev. Growth (Yr)

53.47%

Rev. Growth (Qtr)

-7.19%

RZLT Earnings

Earnings (TTM)

-56.8M

Earnings Growth (Yr)

-2.6%

Earnings Growth (Qtr)

4.23%

Breaking Down RZLT Revenue

Last 7 days

14.0%

Last 30 days

75.5%

Last 90 days

244.1%

Trailing 12 Months

83.8%

How does RZLT drawdown profile look like?

RZLT Financial Health

Current Ratio

12.01

Debt/Equity

0.16

Debt/Cashflow

-3.71

RZLT Investor Care

Shares Dilution (1Y)

7.60%

Diluted EPS (TTM)

-1.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.8M	4.2M	5.2M	5.7M
2022	75.0K	81.0K	480.0K	1.3M
2021	725.0K	63.0K	0	69.0K
2020	1.7M	1.2M	1.2M	1.4M
2019	745.3K	1.3M	1.6M	1.7M
2018	1.2M	762.0K	660.3K	532.5K
2017	661.1K	1.1M	1.2M	1.3M
2016	495.6K	442.0K	466.1K	489.8K
2015	682.7K	539.5K	378.0K	461.1K
2014	502.2K	684.1K	886.4K	838.7K
2013	565.4K	634.1K	597.8K	540.1K
2012	261.7K	0	362.9K	464.2K
2011	0	0	0	160.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rezolute, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	roberts brian kenneth	bought	1,275	2.55	500	chief medical officer
Mar 15, 2024	evans daron	bought	33,830	1.6915	20,000	cfo
Mar 14, 2024	roberts brian kenneth	bought	18,800	1.88	10,000	chief medical officer
Mar 08, 2024	evans daron	bought	96,345	1.9269	50,000	cfo
Mar 07, 2024	roberts brian kenneth	bought	925	1.85	500	chief medical officer
Mar 07, 2024	kim young-jin	bought	69,859	1.9138	36,503	-
Feb 26, 2024	elam nevan c	bought	8,400	1.68	5,000	ceo
Feb 26, 2024	roberts brian kenneth	bought	3,400	1.7	2,000	chief medical officer
Feb 23, 2024	roberts brian kenneth	bought	10,140	1.69	6,000	chief medical officer

Which funds bought or sold RZLT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Vivo Capital, LLC	reduced	-13.73	3,915,620	7,134,140	0.56%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-461,006	1,397,100	-%
Feb 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	unchanged	-	-326,422	989,235	0.16%
Feb 15, 2024	Nantahala Capital Management, LLC	added	299	2,036,470	3,052,350	0.09%
Feb 14, 2024	BVF INC/IL	unchanged	-	-62,492	189,384	-%
Feb 14, 2024	Royal Bank of Canada	added	655	-	-	-%
Feb 14, 2024	UBS OCONNOR LLC	added	7.89	-138,595	597,050	0.04%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	unchanged	-	-206,879	626,952	-%

Are Funds Buying or Selling RZLT?

Are funds buying RZLT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RZLT

No. of Funds

RZLT Alerts

3 major insider buys recently.

Unveiling Rezolute, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	nantahala capital management, llc	9.9%	4,118,164	SC 13G
Feb 13, 2024	vivo opportunity fund holdings, l.p.	8.2%	3,242,842	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	7.0%	2,768,656	SC 13G/A
Feb 12, 2024	first manhattan co. llc.	6.77%	2,680,978	SC 13G/A
Jan 18, 2024	federated hermes, inc.	19.99%	8,250,274	SC 13G/A
Oct 13, 2023	vivo opportunity fund holdings, l.p.	8.8%	3,242,842	SC 13G
May 03, 2023	genexine inc.	4.96%	1,826,019	SC 13D/A
Feb 14, 2023	caxton corp	4.99%	1,860,518	SC 13G/A
Feb 14, 2023	first manhattan co	8.48%	3,123,078	SC 13G
Feb 13, 2023	stonepine capital management, llc	8.2%	3,021,504	SC 13G/A

Recent SEC filings of Rezolute, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	DEF 14A	DEF 14A
Mar 29, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4/A	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	8-K	Current Report

Peers (Alternatives to Rezolute, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-0.89%	-25.81%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	5.17%	-8.18%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-8.90%	-30.41%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.5B	-	-15.28%	57.81%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-11.84%	-2.48%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-11.98%	-22.42%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-3.94%	-8.31%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-12.98%	-52.88%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	7.90%	326.47%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-13.94%	-3.10%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	63.30%	36.92%	-0.25	2.14	-13.45%	66.37%

Rezolute, Inc. News

Latest updates

Rezolute, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-7.2%	1,303	1,404	1,475	1,484	849	400	67.00	-	13.00	1.00	241	481	370	217	319	273	360	711	394	86.00	122
Operating Expenses	-4.5%	15,194	15,914	14,238	17,142	14,392	10,218	11,300	10,754	12,149	6,636	5,483	7,152	3,623	3,552	5,070	6,720	5,179	3,184	17,037	3,161	2,562
S&GA Expenses	-14.7%	3,155	3,700	3,305	2,911	3,447	2,514	2,726	2,068	2,697	2,247	1,725	2,656	1,279	1,107	1,337	1,682	1,945	1,511	1,926	1,773	1,655
R&D Expenses	-1.4%	12,039	12,214	10,933	14,231	10,945	7,704	8,574	8,686	9,452	4,389	3,758	4,496	2,344	2,445	3,733	5,038	3,234	1,718	15,122	1,309	930
Interest Expenses	-	-	-	-	-	-	-	476	331	340	-	-	-	-	-	-	-	-	3,507	43.00	1,288	911
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	4.2%	-13,909	-14,524	-12,741	-15,672	-13,556	-9,831	-9,423	-11,208	-12,593	-6,490	-3,695	-7,097	-3,620	-3,547	-5,040	-6,666	-5,080	-3,147	-19,772	-4,162	-3,365
Net Income Margin	7.4%	-10.03*	-10.84*	-12.31*	-17.32*	-33.45*	-89.70*	-513.25*	-503.33*	-428.17*	-331.78*	-52.90*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-23.0%	-13,020	-10,585	-11,400	-18,018	-7,576	-7,659	-12,110	-13,968	-7,197	-5,230	-5,397	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.6%	102	113	124	134	150	156	152	70.00	83.00	39.00	43.00	33.00	39.00	7.00	11.00	15.00	21.00	27.00	12.00	15.00	8.00
Current Assets	-6.4%	96.00	103	105	106	148	156	152	64.00	78.00	38.00	42.00	32.00	38.00	7.00	11.00	14.00	20.00	26.00	12.00	15.00	0.00
Cash Equivalents	55.2%	13.00	8.00	16.00	34.00	147	154	150	63.00	82.00	37.00	41.00	32.00	38.00	6.00	10.00	14.00	18.00	22.00	38.00	15.00	0.00
Net PPE	-7.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Liabilities	10.6%	10.00	9.00	8.00	7.00	9.00	3.00	3.00	18.00	21.00	17.00	17.00	4.00	3.00	3.00	4.00	4.00	6.00	6.00	11.00	11.00	10.00
Current Liabilities	11.2%	8.00	7.00	5.00	4.00	6.00	2.00	2.00	3.00	6.00	3.00	2.00	4.00	3.00	3.00	3.00	4.00	6.00	6.00	8.00	7.00	3.00
Long Term Debt	-	-	-	-	-	-	-	-	14.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-11.4%	92.00	104	116	127	141	153	149	52.00	62.00	22.00	26.00	29.00	36.00	4.00	7.00	10.00	15.00	21.00	2.00	5.00	-
Retained Earnings	-5.0%	-289	-275	-260	-248	-232	-219	-209	-199	-188	-175	-168	-161	-157	-150	-147	-143	-138	-131	-126	-123	-101
Additional Paid-In Capital	0.5%	381	379	377	376	374	372	359	252	251	198	194	191	194	155	155	154	153	152	129	97.00	92.00
Shares Outstanding	7.6%	40.00	37.00	37.00	37.00	51.00	51.00	34.00	14.00	16.00	9.00	8.00	7.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	64.00	-	-	-	61.00	-	-	-	76.00	-	-	-	13.00	-	-	-	4.00

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-23.0%	-13,020	-10,585	-11,400	-18,018	-7,493	-7,589	-12,110	-13,968	-7,197	-6,341	-5,230	-5,397	-6,263	-3,551	-4,078	-5,679	-5,482	-8,929	-3,765	-8,456	-1,651
Share Based Compensation	-0.6%	1,837	1,849	1,803	1,855	1,731	1,879	984	850	1,009	842	1,660	530	1,141	634	583	675	665	1,394	247	695	816
Cashflow From Investing	581.5%	17,760	2,606	-6,357	-94,954	-83.00	-70.00	-	-	-	-	-	-	-	-	-	-	-	-	-6.00	42.00	8.00
Cashflow From Financing	-	-	-	-	-	-	11,571	94,104	-19.00	52,308	2,586	14,288	-214	37,459	-	-	-	-21.00	22,571	-	23,500	1,500

RZLT Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 12,039	$ 10,945	$ 24,253	$ 18,649
General and administrative	3,155	3,447	6,855	5,961
Total operating expenses	15,194	14,392	31,108	24,610
Operating loss	(15,194)	(14,392)	(31,108)	(24,610)
Non-operating income (expense):
Interest and other income, net	1,303	849	2,707	1,249
Loss from change in fair value of derivative liability	(18)	(13)	(32)	(26)
Total non-operating income, net	1,285	836	2,675	1,223
Net loss	(13,909)	(13,556)	(28,433)	(23,387)
Other comprehensive income:
Net unrealized gain on available-for-sale marketable debt securities	236		303
Comprehensive loss	$ (13,673)	$ (13,556)	$ (28,130)	$ (23,387)
Net loss per common share - basic (in dollars per share)	$ (0.27)	$ (0.26)	$ (0.55)	$ (0.46)
Net loss per common share - diluted (in dollars per share)	$ (0.27)	$ (0.26)	$ (0.55)	$ (0.46)
Weighted average number of common shares outstanding - basic (in shares)	51,408	51,410	51,409	50,969
Weighted average number of common shares outstanding - diluted (in shares)	51,408	51,410	51,409	50,969

RZLT Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 12,504	$ 16,036
Investments in marketable debt securities	80,094	85,860
Prepaid expenses and other	3,487	3,014
Total current assets	96,085	104,910
Long-term assets:
Investments in marketable debt securities	3,352	16,470
Right-of-use assets	2,130	2,054
Property and equipment, net	119	139
Deposits and other	464	148
Total assets	102,150	123,721
Current liabilities:
Accounts payable	3,593	3,269
Accrued liabilities:
Accrued clinical and other	1,394	507
Compensation and benefits	2,483	883
Current portion of operating lease liabilities	538	541
Total current liabilities	8,008	5,200
Long term liabilities:
Operating lease liabilities, net of current portion	1,975	1,937
Embedded derivative liability	439	412
Total liabilities	10,422	7,549
Commitments and contingencies (Notes 5, 9 and 10)
Shareholders' equity:
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 39,625 and 36,827 shares as of December 31, 2023 and June 30, 2023, respectively	40	37
Additional paid-in capital	381,154	377,471
Accumulated other comprehensive loss	(48)	(351)
Accumulated deficit	(289,418)	(260,985)
Total shareholders' equity	91,728	116,172
Total liabilities and shareholders' equity	$ 102,150	$ 123,721

About Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CEO	Mr. Nevan Charles Elam J.D.
WEBSITE	rezolutebio.com
INDUSTRY	Biotechnology
EMPLOYEES	47

Rezolute, Inc. Frequently Asked Questions

What is the ticker symbol for Rezolute, Inc.? What does RZLT stand for in stocks?

RZLT is the stock ticker symbol of Rezolute, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rezolute, Inc. (RZLT)?

As of Mon Apr 22 2024, market cap of Rezolute, Inc. is 140.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RZLT stock?

You can check RZLT's fair value in chart for subscribers.

What is the fair value of RZLT stock?

You can check RZLT's fair value in chart for subscribers. The fair value of Rezolute, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rezolute, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RZLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rezolute, Inc. a good stock to buy?

The fair value guage provides a quick view whether RZLT is over valued or under valued. Whether Rezolute, Inc. is cheap or expensive depends on the assumptions which impact Rezolute, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RZLT.

What is Rezolute, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, RZLT's PE ratio (Price to Earnings) is -2.47 and Price to Sales (PS) ratio is 24.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RZLT PE ratio will change depending on the future growth rate expectations of investors.